Interra Health announced support for Medicare patients under its GLP-1 Bridge program, aiming to make monthly GLP-1 therapy more affordable by covering $50 per month. The move targets a key access problem for older adults who may face cost barriers even when clinical indications are met. For pharma and health-tech partners, the program signals continued operational innovation around coverage gaps and patient adherence. It also highlights the growing role of non-traditional intermediaries to help manufacturers and payers translate demand into sustained utilization. While the headline is affordability-focused, the downstream impact is adherence and persistence—metrics that regulators and payers increasingly monitor for effectiveness in routine practice. The initiative may also intensify competition among assistance programs as GLP-1s broaden to additional indications and patient populations.